PubMed Health⌕ Search

Biomedical subjects

J Marosi

Publications and source records attributed to J Marosi.

At least 19 recordsLinked to original sources
PubMed2001

Validity and reliability of leonhard's classification of endogenous psychoses: preliminary report on a prospective 25- to 30-year follow-up study.

A 25- to 30-year controlled follow-up investigation of endogenous psychoses started in 1997. The research program labeled "Budapest 2000" was initiated in 1967 as a controlled prospective study. The assessment of 108 patients and 24 normal control persons has so far been completed. With regard to the "middle groups" in the Leonhardian classification, diagnoses of bipolar manic-depressive psychosis, cycloid psychosis, periodic catatonia, systematic paraphrenia, systematic catatonia and hebephrenia proved to be valid in the long term. Revision of the category affect-laden paraphrenia seems to be called for.

Female↗
PubMed1977

Comparison of the antidiuretic effects of single intravenous and intranasal doses of DDAVP in diabetes insipidus.

In 13 patients with hypothalamic diabetes insipidus after daily single intravenous (0.04-24 mug) and single intranasal (5-320 mug) doses of 1-deamino-8-D-arginine vasopressin (DDAVP) the relationships between the log doses and antidiuretic responses (log osmolalities of 24-hour urine samples) were compared. On the basis of such comparisons the ratio of nasal per venous daily single dose requirement was determined and found to be 26:1. Similarly, the relative potency of venous DDAVP was investigated in two subgroups of patients classified according to their response to peroral drugs. Seven times more DDAVP was required for patients treated previously with high doses of peroral antidiuretics. It was concluded that in groups of patients with divergent peroral dose requirements different DDAVP single-dose treatment schedules should be planned.

Administration, Intranasal↗
PubMed1976

Individual differences in the antidiuretic response induced by single doses of 1-deamino-8-D-arginine-vasopressin (DDAVP) in patients with pituitary diabetes insipidus.

Marked interindividual differences were found in the height and duration of the antidiuretic action induced by increasing single intravenous doses (0.5 mug and 8 mug) of DDAVP in patients with pituitary diabetes insipidus. It was assumed that differences in the duration of action reflected individual variations in the rate of removal of vasopressin.

Deamino Arginine Vasopressin↗
PubMed1976

Shortened duration of action of 1-deamino-8-D-arginine vasopressin (DDAVP) in patients with diabetes insipidus requiring high doses of peroral antidiuretic drugs.

The antidiuretic effects of graded intravenous and intranasal doses of a new vasopressin analogue (DDAVP) were investigated in two groups of patients with pituitary diabetes insipidus. In the first group, three patients with a high requirement of maintenance doses of peroral anti-diuretic drugs were included; and in the second group, ten patients with a normal (usual) requirement were included. Comparing the antidiuretic responses during 24-hour collection periods, DDAVP, on a microgram basis, was less effective in the "high peroral-dose requirement" patients. The duration of action of single intravenous doses (0.04-24 micrograms) of DDAVP was significantly shortened in the "high peroral-dose requirement" group. However, comparing the peak responses induced by increasing doses of DDAVP in the two groups, there was no demonstrable diminution in the anti-diuretic ability of DDAVP in the "high peroral-dose requirement" patients. Although the possibility of a smaller remnant reserve of ADH was also considered, shortened duration of action ot DDAVP suggests more probably enhanced metabolic breakdown of vasopressin in "high peroral-dose requirement" patients.

Adult↗
PubMed1976

The antidiuretic action of 1-deamino-8-D-arginine vasopressin (DDAVP) in man.

1. After administration of a new vasopressin analogue (DDAVP), a marked and prolonged antidiuresis occurred in 10 patients with pituitary diabetes insipidus. 2. The antidiuretic effects of single intravenous doses of 0.04--24 mug DDAVP and single intranasal doses of 5--320 mug DDAVP were investigated. Time curves of the antidiuretic responses expressed in changes of urine osmolality (Uosm) and free water clearance per 100 ml GFR (CH2O X 100/GFR) are described. 3. Maximal "peak" response was obtained after an intravenous dose of 1 mug within the first 12 hrs (Uosm was 7--800 mOsm/KgH2O). Further increase of dosage resulted only in prolongation of duration of action (up to 48 hrs) and peak ("plateau") effect (up to 24 hrs). 4. There was a linear relationship between the log dose and log osmolality of urine collected in the second 12 hours after administration of single intravenous and intranasal doses of DDAVP. 5. Comparison of the effects of 1 mug lysine-vasopressin and 1 mug DDAVP revealed only slight differences in peak effects, but extreme differences in duration of action. 6. It is concluded that in the evaluation of a synthetic vasopressin analogue the maximal antidiuretic ability and the prolongation of action have to be analysed separately.

Absorption↗
PubMed1976

Lengthening of the duration of action of DDAVP by "ineffective" doses of clofibrate in patients with pituitary diabetes insipidus.

Duration of action of single intravenous and intranasal doses of 1-Deamino-8D-Arginine Vasopressin (DDAVP) was lengthened by "ineffective" doses of clofibrate (not affecting water metabolism when administered alone) in patients with pituitary diabetes insipidus. This interaction was observed when as low doses as 0.02 mug DDAVP were administered intravenously to one patient and as high doses as 1 and 2 mug DDAVP were given intravenously to another patient. Administration of less or more DDAVP than "optimal" for the interaction resulted in decreased or absent potentiation by clofibrate. The exact cause of the interaction is unknown.

Clofibrate↗
PubMed1975

Relationship between the dose of 1-deamino-8-d-arginine vasopressin (ddavp) and the antidiuretic response in man.

A definite relationship was found between the dose of DDAVP (1-24 mug intravenously and 5-320 mug intranasally) and the antidiuretic effects (expressed in changes in free water clearance per 100 ml GFR and in urine osmolality determined in 24 hour urine collection periods) in 7 patients with diabetes insipidus. The relationship was more conspicuous when the second 12 hour antidiuretic responses were considered, indicating a dose-dependent prolongation of the antidiuretic action. Time-curves of the antidiuretic responses proved the dose-dependent prolongation of the duration of antidiuretic action. Second 12 hour antidiuretic response increased more markedly when DDAVP was given divided in two doses a day as compared to the effects of the same quantity of the drug given as a single dose; only by the administration of excessive single doses the effects of the divided doses could be reproduced.

Deamino Arginine Vasopressin↗